keyword
MENU ▼
Read by QxMD icon Read
search

Crohn's:8

keyword
https://www.readbyqxmd.com/read/28928769/exclusive-enteral-nutrition-versus-infliximab-in-inducing-therapy-of-pediatric-crohn-s-disease
#1
Youyou Luo, Jindan Yu, Jingan Lou, Youhong Fang, Jie Chen
AIM: To compare the effectiveness of exclusive enteral nutrition (EEN) and infliximab (IFX) therapy in pediatric Crohn's disease (CD). METHODS: In a prospective study of children initiating EEN or infliximab therapy for CD, we compared clinical outcomes using the pediatric Crohn's disease activity index (PCDAI), growth improvement, endoscopic mucosal healing, and adverse effects. Data were measured at baseline and after 8 weeks of therapy. RESULTS: We enrolled 26 children with CD; of whom, 13 were treated with infliximab, 13 with EEN...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28922260/increased-risk-of-inflammatory-bowel-disease-in-a-population-based-cohort-study-of-patients-with-hirschsprung-disease
#2
Anna Löf Granström, Leila Amin, Henrik Arnell, Tomas Wester
OBJECTIVES: Hirschsprung disease (HSCR) has previously been associated with inflammatory bowel disease (IBD). There are no data to show how common this association is. The aim of this study was to assess the risk of IBD in individuals with HSCR in a population-based cohort. METHODS: This was a nationwide, population-based cohort study. The study exposure was HSCR and the study outcome was IBD. The cohort included all individuals with HSCR registered in the Swedish National Patient Register between 1964-2013 and ten age- and sex-matched controls per patient, randomly selected from the Swedish Population Register...
September 16, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28922253/long-term-efficacy-safety-and-immunogenicity-of-biosimilar-infliximab-after-one-year-in-a-prospective-nationwide-cohort
#3
Lorant Gonczi, Krisztina B Gecse, Zsuzsanna Vegh, Zsuzsanna Kurti, Mariann Rutka, Klaudia Farkas, Petra A Golovics, Barbara D Lovasz, Janos Banai, Laszlo Bene, Bea Gasztonyi, Tunde Kristof, Laszlo Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Maria Papp, Arpad Patai, Agnes Salamon, Tamas Szamosi, Zoltan Szepes, Gabor T Toth, Aron Vincze, Balazs Szalay, Tamas Molnar, Peter L Lakatos
BACKGROUND: It has been previously shown that biosimilar infliximab CT-P13 is effective and safe in inducing remission in inflammatory bowel diseases. We report here the 1-year outcomes from a prospective nationwide inflammatory bowel disease cohort. METHODS: A prospective, nationwide, multicenter, observational cohort was designed to examine the efficacy and safety of CT-P13 in the induction and maintenance treatment of Crohn's disease (CD) and ulcerative colitis (UC)...
August 23, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28919192/magnetic-resonance-index-of-activity-maria-and-clermont-score-are-highly-and-equally-effective-mri-indices-in-detecting-mucosal-healing-in-crohn-s-disease
#4
Anthony Buisson, Bruno Pereira, Marion Goutte, Maud Reymond, Christophe Allimant, Hélène Obritin-Guilhen, Gilles Bommelaer, Constance Hordonneau
BACKGROUND: Magnetic resonance index of activity (MaRIA) and Clermont score are currently the two main MRI indices that have been validated compared to endoscopy in Crohn's disease (CD). AIMS: To compare the accuracy of MaRIA and Clermont score in assessing CD mucosal healing. METHODS: Fourty-four CD patients underwent prospectively and consecutively MRI and colonoscopy. RESULTS: Considering 207 segments, MaRIA>7 and Clermont score>8...
August 31, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28906316/secondary-loss-of-response-to-infliximab-in-pediatric-crohn-s-disease-does-it-matter-how-and-when-we-start
#5
Rishi Bolia, Jeremy Rosenbaum, Vered Schildkraut, Winita Hardikar, Mark Oliver, Donald Cameron, George Alex
OBJECTIVES: A significant proportion of children with Crohn's disease develop a secondary loss of response (LOR) to infliximab. Our aim was to study the impact of initial treatment strategies on secondary LOR. METHODS: We reviewed the medical records of children with Crohn's disease who received scheduled maintenance infliximab therapy for at least 12 months. We compared children who developed LOR with those who did not; with regards to their clinical and laboratory parameters, disease phenotype and treatment strategy before developing LOR...
September 12, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28906288/ibd-live-series-case-8-treatment-options-for-refractory-esophageal-crohn-s-disease-and-hidradenitis-suppurativa
#6
Heba Iskandar, Julia B Greer, Alyssa M Krasinskas, Andrew T Tinsley, Walter A Koltun, Corey A Siegel, L Campbell Levy, Hans H Herfarth, Francis A Farraye, David G Binion, Joel R Rosh, David J Keljo, Kim L Isaacs, Miguel D Regueiro
No abstract text is available yet for this article.
October 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28903094/effectiveness-of-mesalazine-thiopurines-and-tumour-necrosis-factor-antagonists-in-preventing-post-operative-crohn-s-disease-recurrence-in-a-real-life-setting
#7
Mariangela Allocca, Rosario Landi, Stefanos Bonovas, Gionata Fiorino, Alfredo Papa, Antonino Spinelli, Federica Furfaro, Laurent Peyrin-Biroulet, Alessandro Armuzzi, Silvio Danese
BACKGROUND: Most Crohn's disease (CD) patients develop endoscopic recurrence within one year of intestinal resection. The best treatment method to prevent post-operative CD recurrence remains uncertain. METHODS: A total of 155 CD patients from 2 referral centres, who were undergoing intestinal resection with ileo-colonic anastomosis (January 2004-January 2015), were included. All subjects received preventive therapy with tumour necrosis factor antagonists (anti-TNFs), thiopurinesor mesalazine...
September 14, 2017: Digestion
https://www.readbyqxmd.com/read/28902907/pcr-detection-of-human-herpesviruses-in-colonic-mucosa-of-individuals-with-inflammatory-bowel-disease-comparison-with-individuals-with-immunocompetency-and-hiv-infection
#8
Takayuki Shimada, Naoyoshi Nagata, Koki Okahara, Akane Joya, Tsunefusa Hayashida, Shinichi Oka, Toshiyuki Sakurai, Junichi Akiyama, Naomi Uemura, Hiroyuki Gatanaga
BACKGROUND: Detection of human herpesviruses (HHVs) other than cytomegalovirus (CMV) in colonic mucosa of individuals with inflammatory bowel disease (IBD) remains unknown. This study identified eight HHVs in the colonic mucosa of individuals with IBD and compared the results with immunocompetent and human immunodeficiency virus (HIV)-infected individuals. METHODS: A total of 89 individuals who had colorectal ulcer on colonoscopy were enrolled: 26 with immunocompetency (n = 26), 41 with IBD, and 22 with HIV infection...
2017: PloS One
https://www.readbyqxmd.com/read/28902728/crohn-disease-fdg-pet-ct-before-and-after-initial-dose-of-anti-tumor-necrosis-factor-therapy-to-predict-long-term-response
#9
Yan Epelboym, Paul B Shyn, Jeffrey Forris Beecham Chick, Matthew J Hamilton, Stacy D OʼConnor, Stuart G Silverman, Chun K Kim
PURPOSE: Clinical assessments of Crohn disease activity are limited in their capacity to assess treatment response to biologic therapy. The purpose of this study was to determine if changes in FDG activity between baseline PET and repeat PET performed prior to the second dose of induction anti-tumor necrosis factor (TNF) therapy correlate with clinical response. METHODS: In this prospective, institutional review board-approved, Health Insurance Portability and Accountability Act-compliant pilot study of 8 adult patients with active Crohn disease, FDG activity before and 2 weeks after initiation of anti-TNF therapy was assessed using low-dose PET/CT...
September 11, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28889960/outcomes-after-fecal-diversion-for-colonic-and-perianal-crohn-disease-in-children
#10
Rajmohan Dharmaraj, Melodee Nugent, Pippa Simpson, Marjorie Arca, Bhaskar Gurram, Steven Werlin
BACKGROUND: Temporary fecal diversion by means of an ileostomy or colostomy has been used in the surgical management of refractory colonic and perianal Crohn disease (CD). The aims of our study were to evaluate the outcomes after fecal diversion in pediatric patients with colonic and perianal CD. METHODS: The records of patients who underwent fecal diversion for colonic and perianal CD at Children's Hospital of Wisconsin between July 2000 and June 2014 were reviewed retrospectively...
August 24, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/28885229/impact-of-diagnostic-delay-and-associated-factors-on-clinical-outcomes-in-a-u-s-inflammatory-bowel-disease-cohort
#11
Vu Q Nguyen, Dingfeng Jiang, Sharon N Hoffman, Srikar Guntaka, Jessica L Mays, Anthony Wang, Joseph Gomes, Dario Sorrentino
BACKGROUND: The impact of diagnostic delay in inflammatory bowel disease, including Crohn's disease (CD) and ulcerative colitis (UC), on disease course remains uncertain. This study examines factors that may influence time to diagnosis and disease outcomes in a U.S. patient cohort. METHODS: We retrospectively collected data on patient characteristics, time to diagnosis, disease phenotype, and complications in 177 patients with inflammatory bowel disease (110 CD and 67 UC) diagnosed at our institution from 2008 to 2015...
September 6, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28884856/significance-of-measurement-of-serum-trough-level-and-anti-drug-antibody-of-adalimumab-as-personalised-pharmacokinetics-in-patients-with-crohn-s-disease-a%C3%A2-subanalysis-of-the-diamond-trial
#12
H Nakase, S Motoya, T Matsumoto, K Watanabe, T Hisamatsu, N Yoshimura, T Ishida, S Kato, T Nakagawa, M Esaki, M Nagahori, T Matsui, Y Naito, T Kanai, Y Suzuki, M Nojima, M Watanabe, T Hibi
BACKGROUND: Significance of monitoring adalimumab trough levels and anti-adalimumab antibodies (AAA) for disease outcome in Crohn's disease (CD) patients remained unclear. AIM: To evaluate the association of adalimumab trough levels and AAA at week 26 with clinical remission at week 52, the effect of azathiopurine on AAA and factors influencing trough levels in CD patients in the DIAMOND trial. METHODS: We performed this study using adalimumab trough levels, AAA at week 26 and 6-thioguanine nucleotide (TGN) in red blood cells at week 12...
September 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28882540/symptoms-of-anxiety-and-depression-are-independently-associated-with-inflammatory-bowel-disease-related-disability
#13
Webber Chan, Hang Hock Shim, Miao Shan Lim, Fatimin Leila Bahjin Sawadjaan, Sangeetha Poongunam Isaac, Sai Wei Chuah, Rupert Leong, Chris Kong
BACKGROUND: Inflammatory bowel disease (IBD) frequently results in disability. The relevance of psychological effects in causing disability, and whether disability occurs similarly in non-Western cohorts is as yet unknown. AIM: We assessed the relationship between symptoms of anxiety and depression, quality of life and disability in a Singaporean IBD cohort and their predictors. METHODS: Cross-sectional study. We assessed consecutive IBD subjects' IBD-Disability Index (IBD-DI), Hospital Anxiety and Depression Scale (HADS), and IBD questionnaire (IBDQ)...
August 14, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28881875/efficacy-safety-and-long-term-outcome-of-serial-endoscopic-balloon-dilation-for-upper-gastrointestinal-crohn-s-disease-associated-strictures-a-cohort-study
#14
Amandeep Singh, Neha Agrawal, Satya Kurada, Rocio Lopez, Hermann Kessler, Jessica Philpott, Bo Shen, Bret Lashner, Florian Rieder
Background: Gastric and duodenal Crohn's disease [CD]-associated strictures are rare. Evidence on endoscopic balloon dilation [EBD] of upper gastrointestinal [GI] CD strictures is limited, in particular in respect to serial dilations. Methods: Prospective short- and long-term outcome data as well as complication rates on a cohort of upper GI CD-associated stricture dilations [stomach and duodenum] were collected from 1999 to 2015. Factors linked with clinical and technical success, long-term efficacy and complication rates were investigated...
September 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28879509/il26-modulates-cytokine-response-and-anti-tnf-consumption-in-crohn-s-disease-patients-with-bacterial-dna
#15
Paula Piñero, Oriol Juanola, Ana Gutiérrez, Pedro Zapater, Paula Giménez, Anna Steinert, Laura Sempere, José M González-Navajas, Jan H Niess, Rubén Francés
Interleukin IL26 supports killing of microbes and the innate sensing of bacterial-derived DNA (bactDNA). We evaluated the relationship between IL26 serum levels and bactDNA translocation in Crohn's disease (CD). We ran a prospective study on CD patients in remission. IL26 common polymorphisms, serum cytokines and complement protein, amplified-bactDNA, and anti-TNF-α were evaluated. In vitro PBMC analysis was performed. Three hundred and thirteen patients were included (mean CDAI: 83.6 ± 32.8; mean fecal calprotectin: 55...
September 6, 2017: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://www.readbyqxmd.com/read/28872665/expression-of-human-cathelicidin-peptide-ll-37-in-inflammatory-bowel-disease
#16
Shoko Kusaka, Atsushi Nishida, Kenichiro Takahashi, Shigeki Bamba, Hiroyuki Yasui, Masahiro Kawahara, Osamu Inatomi, Mitsushige Sugimoto, Akira Andoh
Cathelicidin peptide LL-37 plays an important role in the early host response against invading pathogens via its broad-spectrum antimicrobial activity. In this study, we investigated LL-37 expression in the inflamed mucosa of IBD patients. Furthermore, the regulatory mechanism of LL-37 induction was investigated in human colonic subepithelial myofibroblasts (SEMFs). LL-37 mRNA expression and protein secretion were analyzed using real-time polymerase chain reaction and enzyme-linked immunosorbent assay, respectively...
September 5, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28858439/adherence-to-infliximab-therapy-in-inflammatory-bowel-disease-patients-in-a-real-life-setting
#17
Laura Martelli, Anthony Lopez, Sophie Strobel, Silvio Danese, Xavier Roblin, Cédric Baumann, Laurent Peyrin-Biroulet
AIM: To assess adherence to infliximab therapy in inflammatory bowel disease patients, to investigate reasons for non-adherence and to identify predictors for non-adherence. METHODS: This observational study was conducted in two French referral university hospitals between September 1(st) and October 31(th) 2011. Patients were systematically asked if they had already delayed or missed an infliximab perfusion since the beginning of the treatment and about the reasons for their non-adherence...
August 31, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28858071/efficacy-of-the-autoimmune-protocol-diet-for-inflammatory-bowel-disease
#18
Gauree G Konijeti, NaMee Kim, James D Lewis, Shauna Groven, Anita Chandrasekaran, Sirisha Grandhe, Caroline Diamant, Emily Singh, Glenn Oliveira, Xiaoyun Wang, Bhuvan Molparia, Ali Torkamani
INTRODUCTION: Data suggest dietary modification can improve clinical responses in inflammatory bowel disease (IBD). The goal of this study was to determine the efficacy of an autoimmune protocol diet in patients with Crohn's disease and ulcerative colitis. METHODS: We enrolled adults with active IBD (Harvey-Bradshaw index ≥ 5 or partial Mayo score ≥3 and erosions on endoscopy and/or elevated fecal calprotectin). For the autoimmune protocol, patients underwent 6-week elimination followed by 5-week maintenance phase...
August 29, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28853727/evaluation-of-gastrointestinal-patient-reported-outcomes-measurement-information-system-gi-promis-symptom-scales-in-subjects-with-inflammatory-bowel-diseases
#19
Bharati Kochar, Christopher F Martin, Michael D Kappelman, Brennan M Spiegel, Wenli Chen, Robert S Sandler, Millie D Long
OBJECTIVES: Patient reported outcomes (PROs) are important treatment endpoints in inflammatory bowel diseases (IBD). We evaluated the gastrointestinal (GI) PRO Measurement Information System (PROMIS) in IBD subjects. METHODS: Crohn's and Colitis Foundation of America's Partners is an Internet-based cohort of IBD subjects. Participants complete surveys, including demographics, disease characteristics, PROMIS domains, disease activity (short Crohn's disease activity index or simple clinical colitis activity index) and quality of life (QoL) indices...
August 29, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28852175/risk-factors-for-postoperative-surgical-site-infections-in-patients-with-crohn-s-disease-receiving-definitive-bowel-resection
#20
Song Liu, Ji Miao, Gefei Wang, Meng Wang, Xiuwen Wu, Kun Guo, Min Feng, Wenxian Guan, Jianan Ren
Surgical site infection presents as a significant problem that limits the potential benefits of surgical interventions. This study is to investigate risk factors for postoperative SSI in patients with Crohn's disease receiving definitive bowel resection. A case-control study including 49 patients with SSI and 105 patients without SSI was performed. Demographics, clinical characteristics, laboratory information, medical and surgical data were compared between groups. Significant elements were subsequently brought into logistic regression analysis for further identification...
August 29, 2017: Scientific Reports
keyword
keyword
53050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"